Venetoclax (ABT-199) is a selective, oral bioavailable inhibitor of BCL-2 that has activity in a
variety of hematologic malignancies. 1-3 BCL-2 expression is high in leukemia stem cells of …

Acute myeloid leukemia (AML) is associated with poor outcomes, especially in older patients
in whom the disease is most common. B-cell lymphoma 2 (BCL-2) is an antiapoptotic protein …

Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor
prognosis and represents a major unmet medical need. We report on a real-world academic …

Recent clinical data have shown a synergistic effect of venetoclax in combination with the
hypomethylating agents (HMA) azacitidine and decitabine (complete remission [CR]/CR with …

Patients with acute myeloid leukemia (AML) who progress after exposure to
hypomethylating agents (HMA) have a dismal prognosis. We hypothesized that the addition …

Venetoclax (VEN) is a selective BCL-2 inhibitor that has been shown to be effective when
used in combination with hypomethylating agents (HMAs) or low-dose cytarabine (LDAC) for …

Background Venetoclax in combination with hypomethylating agents (HMA) is
revolutionizing the therapy of acute myeloid leukemia (AML). However, evidence on large …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Outcomes of
intensive chemotherapy (IC) in older patients with AML continue to be suboptimal due to …

The clinical benefit of adding venetoclax (VEN) to hypomethylating agents or low-dose
cytarabine in older and/or unfit patients with newly diagnosed acute myeloid leukemia (AML) …

Venetoclax and hypomethylating agent (HMA) combination therapy is FDA‐approved for
elderly or unfit acute myeloid leukemia (AML) patients unable to withstand intensive …